Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • TAK-079

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

    Around 700,000 people in the US are living with some form of the autoimmune disease

    - PMLiVE

    BMS and Bain Capital launch new company to develop immunology therapies

    The newly formed company has in-licensed five investigational immunology drugs from BMS

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

    The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

    - PMLiVE

    AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis

    The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Pfizer and Flagship Pioneering enter autoimmune disease partnership

    More than 100 known types of autoimmune diseases affect over 50 million people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links